Genocea Biosciences
GNCA
$0.0001000
Share price
-85.71%
Change (1 day)
N/A
Change (1 year)
Categories
Genocea Biosciences (GNCA) - Cash on Hand
Cash on Hand as of March 2022 : $20.13 M
According to Genocea Biosciences
's latest financial reports the company has $20.13 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Genocea Biosciences - Cash on Hand chart (from 2012 to 2022)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2021-12-31 | $37.14 M | -53.43% |
| 2020-12-31 | $79.76 M | 98.79% |
| 2019-12-31 | $40.12 M | 52.22% |
| 2018-12-31 | $26.36 M | 114.79% |
| 2017-12-31 | $12.27 M | -80.63% |
| 2016-12-31 | $63.36 M | -32.83% |
| 2015-12-31 | $94.32 M | 100.36% |
| 2014-12-31 | $47.07 M | 285.64% |
| 2013-12-31 | $12.2 M | 6.01% |
| 2012-12-31 | $11.51 M | 100.56% |
| 2011-12-31 | $5.74 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 62,918.32% | 🇺🇸 USA |
 Merck MRK | $7.09 B | 35,123.72% | 🇺🇸 USA |
 Novavax NVAX | $0.56 B | 2,723.19% | 🇺🇸 USA |
 Agenus
AGEN | $76.11 M | 277.96% | 🇺🇸 USA |
 iBio IBIO | $2.78 M | -86.15% | 🇺🇸 USA |